Of Congress and Cures [STAT Summit 2026 Review #20]

Report 20. Of Congress and Cures

Part I. English Version

1. Event / Date & Time

Event: Of Congress and Cures

Conference: STAT Summit 2026

Date & Time: October 15, 2026 | 9:35 AM EDT

2. Participants

Speakers

- Jake Auchincloss — U.S. Representative, Massachusetts 4th Congressional District

Moderator

- Chelsea Cirruzzo — Washington Correspondent, STAT

3. Summary

Biotechnology Competitiveness: Representative Jake Auchincloss favored strengthening U.S. research and development capacity over relying predominantly on restrictions targeting China.

Clinical Trial Reform: Faster and more practical domestic early-stage trials were proposed as a way to improve U.S. competitiveness despite differences in cost.

Science Policy and Talent: Research funding stability, independent peer review and openness to international scientific talent were presented as key factors in biomedical leadership.

4. Main Discussion

Compete by Accelerating Innovation

Auchincloss argued that the policy choice is between helping the United States innovate faster and attempting to block China’s progress. He acknowledged China’s advanced preclinical and Phase 1–2 research capacity but warned that restricting access or weakening U.S. institutions would not build domestic strength. His remarks reflected a policy position rather than an agreed bipartisan program.

Auchincloss framed biotechnology as a strategic national asset but challenged the assumption that excluding China is a sufficient industrial strategy. In his comparison, Chinese scientists and developers will continue to expand capacity regardless of U.S. restrictions, including more standardized preclinical work and early clinical development. The relevant question, in his view, is whether American institutions can accelerate discoveries and attract companies to conduct development domestically. He strongly criticized policy approaches he considered harmful to immigrant physician-scientists, peer-review independence and FDA competence. Those assessments were the congressman’s political judgments, not consensus findings of the summit. His alternative emphasized increasing U.S. speed, scientific capacity and predictability rather than relying solely on barriers against a competitor.

Auchincloss drew a strategic distinction between slowing China and increasing U.S. research capacity. In his view, efforts focused chiefly on excluding Chinese competition would not substitute for scientific investment, a reliable regulatory system and the ability to bring discoveries into clinical development. He noted China’s scale and growing ability to conduct preclinical work and early-phase trials efficiently, while arguing that the United States could still compete through stronger domestic capabilities. This was an elected official’s policy judgment, not a measured forecast. For biotech leaders the practical question was where public action can accelerate discovery, clinical testing and commercialization rather than merely change which foreign entities are eligible to participate.

Early Clinical Trials and Regulatory Speed

He discussed plans for bipartisan legislation to accelerate U.S. clinical trials, including streamlining institutional review boards and learning from Australia’s Clinical Trial Notification pathway. He accepted that American trials would not necessarily match China’s lower costs but argued that comparable speed would allow companies to choose domestic development.

A concrete target was the interval between identifying a promising biomedical candidate and starting studies in humans. Auchincloss discussed institutional review boards and suggested that fragmented review processes can create avoidable delays for low-risk early-stage research. He cited Australia’s Clinical Trial Notification approach as an example of an environment attractive to sponsors seeking faster trial initiation. His proposed U.S. reforms were described as legislative ideas rather than enacted rules. He acknowledged that China could continue to offer lower costs, but argued that the United States might retain more development activity if domestic trials were comparably fast, credible and easier to initiate. Such reforms would need to preserve participant protection and confidence in regulatory oversight.

The congressional discussion linked the science ecosystem to people and institutions that are often treated as separate policy subjects. Auchincloss criticized immigration measures he believed would discourage international students, physicians and scientists from working in the United States. He also questioned politicization of NIH peer review and changes that, in his assessment, weakened confidence in FDA processes. Such concerns matter because a drug-development program depends on grant-funded discoveries, investigators able to work across borders, consistent scientific assessment and predictable approvals. The session exposed the potential cumulative effect of small disruptions across this chain, although it did not quantify the size of any individual policy effect.

Immigration, Peer Review and Research Capacity

Auchincloss criticized restrictions on immigrant scientists and political pressures on research peer review, noting the Boston life-sciences ecosystem’s reliance on international talent. He argued that federal research policy and FDA credibility influence the country’s ability to turn discoveries into medicines. He also emphasized Massachusetts’s strength in the earliest stages of target discovery.

The conversation linked research infrastructure to workforce conditions and the credibility of public agencies. In biotechnology, highly trained immigrants can move among universities, teaching hospitals, startups and larger drug developers; disruptions in that mobility may affect multiple stages of development. Auchincloss described research peer review and FDA scientific competence as assets that enable investors and patients to trust decisions. He also contrasted the rich discovery ecosystem around Boston with the challenge of retaining activities farther along the development chain. The implication of his argument was that early discovery, initial clinical studies, financing and regulatory review are interconnected parts of a competitive system rather than interchangeable services that can be moved without cost.

The moderator pressed the congressman on the place of bipartisan legislation, emerging therapies and the commercial incentives required to carry risky science through development. He argued that U.S. policy should emphasize the affordability of innovation alongside incentives to create it, rather than present the two as mutually exclusive. His perspective was shaped in part by the Massachusetts research economy, where he cited a substantial flow of NIH research grants. Importantly, the exchange described a political debate, not the enactment of a particular bill or a definitive conclusion about how China-related restrictions will operate. It therefore calls for careful monitoring of concrete legislative text and implementation.

Rebuilding Public Support for Biotech

The congressman urged industry to explain not only its contribution to new cures but also its role in creating research and manufacturing jobs. Discussion covered public skepticism about pharmaceutical companies and ways policy debates could reflect both patient benefits and economic value.

Auchincloss also pressed biotechnology companies to make a broader public case for their industry. Patients may experience the sector through high medicine prices, while communities may not see the training, scientific employment and manufacturing activities associated with successful innovation. He argued that the industry should connect its claims about cures to evidence of concrete economic and health benefits. In that account, public support is important for maintaining federal research investment and a policy environment receptive to innovation. The session did not resolve questions of drug affordability or U.S.–China policy; rather, it juxtaposed competition, regulatory performance, immigration and public legitimacy as interdependent issues for national biomedical strategy.

In the question-and-answer portion, concerns raised by international students broadened the debate beyond institutional budgets. The ability to recruit and retain trainees affects laboratory continuity, clinical research teams and the creation of future biotech companies. Auchincloss argued for a domestic strategy that recognizes immigrant scientific talent as an advantage rather than a vulnerability. Whether that view produces policy change remains uncertain, but the discussion identifies workforce stability as a long-horizon research input. A laboratory may regain a grant after a disruption, whereas an interrupted training cohort or a researcher who relocates may be harder to replace.

5. Insights

Competitive Research Infrastructure: Domestic discovery and early clinical capacity can be as important as market restrictions in sustaining biomedical leadership.

Implications for South Korea: Korea could examine opportunities to accelerate early clinical research while protecting scientific review quality and research continuity.

Global Talent and Partnerships: International researchers and cross-border collaborations remain important assets even as biotechnology is treated as a strategic sector.

Report 20. Of Congress and Cures_eng.pdf

Download PDF • 71KB